Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
- PMID: 29564549
- PMCID: PMC5953992
- DOI: 10.1007/s00296-018-4005-5
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
Abstract
Current guidelines for the management of rheumatoid arthritis (RA) recommend early treatment and a treat-to-target goal of remission or low disease activity. Over the past decade, this approach has been extremely successful in reducing disease activity and joint damage in patients with RA. At the same time, however, overall patient perception of well-being appears to have decreased with respect to outcome measures considered important by patients themselves, such as pain, fatigue, physical function and quality of life. The timely and effective use of patient-reported outcomes (PROs) could encourage physicians to focus more on the impact of RA on patients and how patients are feeling. This in turn would facilitate shared decision making between patients and physicians, ultimately leading to a more patient-centered approach and improved patient care. Indeed, PROs provide information about individual patients that complements information provided by physical assessment and composite scores, and can also be used to guide patient care, such as determining whether a clinic visit is needed or whether treatment modifications are necessary. This is particularly important for patients who do not achieve the aspirational target of remission or low disease activity with pharmacological treatment. A number of validated PRO questionnaires are available, but how and which PROs should be incorporated into rheumatology clinical practice as part of the decision-making process is still controversial. Combining PROs with technology, such as computer adaptive tests, electronic PRO systems, web-based platforms and patient dashboards, could further aid PRO integration into daily rheumatology clinical practice.
Keywords: Fatigue; Pain; Patient-reported outcomes; Quality of life; Rheumatoid arthritis.
Conflict of interest statement
Human participants and animal rights statement
For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
Bruno Fautrel has received research grants from AbbVie, MSD and Pfizer, and consultancy fees from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Janssen, Lilly, Medac, Nordic, Pfizer, Roche, and UCB. Rieke Alten has received research grants from UCB, Lilly, Janssen and Pfizer, and consultancy fees from Roche, UCB, Celgene, BMS, Lilly, MSD, AstraZeneca, Pfizer, Janssen, AbbVie, Biogen, Galapagos and Sandoz. Bruce Kirkham has received research grants from UCB, Lilly, AbbVie and Novartis, and consultancy fees from Lilly, Novartis and Janssen. Peter C. Taylor has received research grants from UCB, Lilly, Janssen and Celgene, and consultancy fees from Roche, UCB, GSK, BMS, Lilly, MSD, Pfizer, Janssen, AbbVie, Biogen, Galapagos and Sandoz. Inmaculada de la Torre, Frederick Durand, Jane Barry, Thorsten Holzkaemper and Walid Fakhouri are all medical members of the International Rheumatology Area at Eli Lilly and Company, and employees of Eli Lilly and Company.
Similar articles
-
Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes.Arthritis Care Res (Hoboken). 2013 Oct;65(10):1707-12. doi: 10.1002/acr.22048. Arthritis Care Res (Hoboken). 2013. PMID: 23740824
-
Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.Trials. 2019 Mar 22;20(1):182. doi: 10.1186/s13063-019-3272-0. Trials. 2019. PMID: 30902094 Free PMC article.
-
"Am I OK?" using human centered design to empower rheumatoid arthritis patients through patient reported outcomes.Patient Educ Couns. 2019 Mar;102(3):503-510. doi: 10.1016/j.pec.2018.10.016. Epub 2018 Oct 28. Patient Educ Couns. 2019. PMID: 30446358 Free PMC article.
-
Patient-driven outcomes in rheumatoid arthritis.J Rheumatol Suppl. 2009 Jun;82:33-8. doi: 10.3899/jrheum.090129. J Rheumatol Suppl. 2009. PMID: 19509328 Review.
-
Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.Health Technol Assess. 2018 Nov;22(66):1-294. doi: 10.3310/hta22660. Health Technol Assess. 2018. PMID: 30501821 Free PMC article.
Cited by
-
Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?Lancet Rheumatol. 2020 Aug;2(8):e454-e456. doi: 10.1016/S2665-9913(20)30175-2. Epub 2020 Jun 8. Lancet Rheumatol. 2020. PMID: 32835250 Free PMC article. No abstract available.
-
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.Arthritis Res Ther. 2020 Oct 15;22(1):243. doi: 10.1186/s13075-020-02324-7. Arthritis Res Ther. 2020. PMID: 33059710 Free PMC article. Clinical Trial.
-
"Mastering a New Life Situation" - Patients' Preferences of Treatment Outcomes in Early Rheumatoid Arthritis - A Longitudinal Qualitative Study.Patient Prefer Adherence. 2020 Aug 13;14:1421-1433. doi: 10.2147/PPA.S253507. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32884244 Free PMC article.
-
The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study.Rheumatol Adv Pract. 2020 Sep 16;4(2):rkaa041. doi: 10.1093/rap/rkaa041. eCollection 2020. Rheumatol Adv Pract. 2020. PMID: 32964180 Free PMC article.
-
Development, psychometric evaluation and cognitive debriefing of the rheumatoid arthritis symptom and impact questionnaire (RASIQ).J Patient Rep Outcomes. 2021 Dec 11;5(1):129. doi: 10.1186/s41687-021-00400-3. J Patient Rep Outcomes. 2021. PMID: 34894330 Free PMC article.
References
-
- Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;0:1–18. - PubMed
-
- Haugeberg G, Boyesen P, Helgetveit K, Proven A. Clinical and radiographic outcomes in patients diagnosed with early rheumatoid arthritis in the first years of the biologic treatment era: a 10-year prospective observational study. J Rheumatol. 2015;42(12):2279–2287. doi: 10.3899/jrheum.150384. - DOI - PubMed
-
- Nieuwenhuis WP, de Wit MPT, Boonen A, van der Helm-van Mil AHM. Changes in the clinical presentation of patients with rheumatoid arthritis from the early 1990s to the year 2010: earlier identification but more severe patient reported outcomes. Ann Rheum Dis. 2016;75(11):2054–2056. doi: 10.1136/annrheumdis-2016-209949. - DOI - PubMed
-
- Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati.... Accessed 12 Jan 2017 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous